Department of Extracorporeal Immunomodulation

The Fraunhofer project group Extracorporeal Immunomodulation (EXIM) in Rostock is dedicated to the development of new diagnostic and treatment procedures in the field of extracorporeal organ replacement systems. Here, work is focused around innovative systems which support the immune system, as well as on functional analyses, improvements to existing medical engineering systems, cell culture based in vitro diagnostics and clinical trials.

The group offers the entire spectrum of preclinical and clinical analyses of extracorporeal technologies based on a broad spectrum of in vitro simulations and animal models as well as on a strong clinical study network for in- and out-patients. Furthermore, the group offers a range of analytical and diagnostic methods, including a cell sensor it developed itself and various molecular assays. By drawing on its close-knit network of cooperation partners, the group also has access to additional state-of-the-art technologies.

The project group is funded by:

Logo Ministry of Education, Science and Culture Mecklenburg-Vorpommern

ASSESS-MED – Service Center for the Assessment of Medical Devices


Before medical devices can be developed, produced and distributed on the market, special requirements first have to be met. Strict regulatory demands are placed on medical devices in order to transfer new therapeutic approaches or innovative products into clinical application and exploit them commercially. These requirements help ensure optimal product and patient safety. European conformity (CE) often implies high costs for companies, which is why experienced external experts, though not usually research institutes, are regularly called upon to verify that these requirements have been met (in the form of CE marking).

Thanks to the close collaboration between engineers, scientists and medical practitioners at Rostock's EXIM Unit, stretching back decades in some cases, the unit has the respective expertise, as seen in particular in the development and testing of new blood purification procedures and products right over to their successful market launch.

Project aims and vision:

The basic idea behind the submitted project is to create a central facility for all companies and institutes that develop and produce medical devices, particularly in the field of blood purification, both on a regional and national level. Cost-intensive resources such as a certified test laboratory with qualified staff can be used by companies as an external service as and when required. Having a suitably accredited test laboratory on hand makes things a lot easier for the manufacturer as they work towards placing their product on the market. The project aims to establish a specialized, independent facility for assessing medical devices for blood purification and create the bases for its economic operation following start-up funding. The goal here is to become accredited as a test laboratory for medical devices by the German accreditation body (DAkkS). There is also a strong possibility that a spin-off can be founded once the funding period has expired.

The project is being funded using means provided by the European Union made available through the European Regional Development Fund (ERDF) and the Ministry for Economic Affairs, Labor and Health of Mecklenburg-West Pomerania

Funding reference number: GW-19-0001

Logo Europäische Fonds EFRE, ESF und ELER in Mecklenburg-Vorpommern
Logo Mecklenburg-Vorpommern

Cryoregeneration of dialysate

The wash column is central to automating the cryoprocedure
© Fraunhofer IZI

The wash column is central to automating the cryoprocedure.

Patients whose bodies have a weakened detoxification function due to a late-stage chronic kidney disease regularly need to have dialysis. The principle behind this procedure has been established for decades and is based on extracting water-soluble toxins (uremia toxins) in an extracorporeal filter, i.e. the dialyzer. The toxins pass from the blood into the purifying dialysis water (dialysate) via a membrane in the dialyzer. Around 120 liters of dialysate are required for every dialysis treatment, which usually takes four hours and is repeated three times a week. This water is taken from reverse osmosis (RO) plants in hospitals and specialized dialysis practices. Not only do these plants take up a lot of space and energy, but the water can only be used once as it disappears as waste water following dialysis. Based on a one-year time frame and 90 000 patients in Germany, over 1.7 million cubic meters of highly purified water are needed, without even taking the lost RO water into account.

Based on an approach which has never been applied to dialysis in the past, a procedure is being developed in the Department of Extracorporeal Immunomodulation that facilitates the regeneration of used dialysis water and could therefore completely change the huge problem of water dependability affecting the use of dialysis today. This procedure draws on the concept of freeze concentration used in the beverage industry and is based on the principle that the crystal lattice structure of frozen water excludes any previously dissolved foreign substances. As part of an automatable cycle, the procedure enables contaminated dialysate to be separated into pure water and a small residual volume containing impurities. This residual volume may arise from the patient’s regular liquid intake, removing the dialysis’ dependency on a pure water supply and making entirely mobile solutions conceivable. The fact that this separation occurs regardless of substance properties such as solubility, polarity, size, density, etc. is hugely beneficial compared with all conventional filter-based procedures, which do not demonstrate a sufficient filter capacity, especially for urea.

The procedure is currently being patented and an automated solution is undergoing development. This technical solution will then be used to carry out extensive investigations to specify process parameters that can later be used when working towards the initial clinical application. Notable industrial companies have already shown an interest in the procedure despite it’s early stage of development.

3D Tissue Model Systems

This sub-project forms part of the HOGEMA joint project: "Researching novel approaches to provide improved tissue replacement materials based on hydrostatic high-pressure treatment".

The project sees partners from the University of Rostock, Greifswald University Hospital, Wismar University of Applied Sciences, Fraunhofer IZI and the University of Rostock's Department of Medicine working together to explore new ways of providing more effective tissue replacement materials based on hydrostatic high-pressure treatment.

Fraunhofer IZI’s Extracorporeal Immunomodulation Unit (EXIM) will investigate the applicability of hydrostatic high-pressure technology in rodents, looking at soft tissue such as the kidneys or intestines. The aim here is to produce tissue scaffolds with a much higher matrix integrity than when using wet chemical methods. By subsequently repopulating the scaffolds with human cells, these models can be used for a number of medical, pharmacological and biotechnical investigations.

More information on the "HOGEMA" research alliance can be found at:

The project is supported using funds provided by the European Social Fund (ESF) within the scope of the qualification program "Promotion of junior scientists in outstanding research alliances – excellence in research program of the state of Mecklenburg-Western Pomerania".

Funding reference number: ESF/14-BM-A55-0012/18

Logo Europäische Fonds EFRE, ESF und ELER in Mecklenburg-Vorpommern
Logo Mecklenburg-Vorpommern

EXTHER – Extracorporeal therapy systems

The EXTHER project area focuses on the development and testing of innovative therapies, in particular those which aim to support the immune system. Novel treatment strategies are developed on the basis of classic extracorporeal technology platforms, such as dialysis and plasma separation. Special emphasis is placed on the development of extracorporeal blood treatment methods for sepsis therapy. Another approach is the development of extension systems for dialysis.


Development of the extracorporeal immune support system (EISS)

Over 18 million people around the world suffer from severe sepsis every year. In Germany alone, up to 60,000 people die from the disease every year. This is why, together with the company Artcline GmbH, the EXIM group has developed and evaluated a cell bioreactor system which can be used to treat sepsis using immune cells (granulocytes) taken from healthy donors. In doing so, the patient's plasma is circulated extracorporeally in a bioreactor with a granulocyte concentrate taken from a donor of a compatible blood group. During this process, bacterial toxins and other inflammatory substances are removed from the blood plasma by means of phagocytosis, allowing the purified patient plasma to be fed back into the patient's bloodstream. Initial clinical results show a clear improvement in patients' cellular immunocompetence, alongside the decrease in bacterial components. Further clinical trials with adjusted parameters are planned for the near future.


Granulocyte purification

This project looks at optimizing the purification of granulocytes, which are required for the extracorporeal immune support system. A key goal here is to extend storage time under currently applicable transfusion medicine conditions. At present, granulocyte concentrates can only be stored for up to 24 hours at 20–24 °C. An increase in the durability of granulocyte concentrates would significantly increase the flexibility of the therapies to be conducted in an everyday clinical setting and also the logistics associated with donations. Furthermore, pure granulocyte concentrations cannot be manufactured at present as the preparation becomes contaminated by a certain amount of erythrocytes and thrombocytes during apheresis. This project therefore also aims to process human blood preparations in such a way that allows the purest granulocyte fraction possible to be obtained and, in turn, optimally used in a clinical and therapeutic context.


Cytokine adsorber

Sepsis, also commonly referred to as blood poisoning, is a complex systemic inflammatory response produced by the body. It is usually triggered by bacteria and their toxins when they manage to enter the bloodstream and results in a powerful immune response which is also directed in part against the patient’s own body. In severe cases, the patient becomes highly susceptible to secondary infections and multiple organ failure. Sepsis and its serious forms of progression is becoming more and more prevalent around the world. This explains why severe cases of sepsis still prove fatal in over 50 per cent of cases today, in spite of the various state-of-the-art intensive care options available. It is essential that the disease is diagnosed and effective antibiotic treatment initiated as quickly as possible: this can mean the difference between life and death. In order to improve a patient’s prognosis, various therapeutic approaches such as renal replacement therapy or adsorptive procedures can be introduced in addition to standard treatment. Hemoperfusion is an important adsorptive procedure, whereby the patient’s blood passes extracorporeally through a cartridge containing an adsorbent. The various commercially available adsorbers target either the removal of toxins (lipopolysaccharides) or of inflammatory mediators (cytokines / chemokines), which are increasingly released during the overreaction of the immune system. This type of cytokine adsorber (CytoSorb) was examined in collaboration with the company CytoSorbents Europe GmbH. CytoSorb adsorption columns are approved in Europe as an auxiliary extracorporeal treatment for sepsis. The columns aim to remove pro- and anti-inflammatory messenger substances from the blood during the immediate defense response where possible. As, however, this adsorption is a non-specific process, investigations were carried out into whether and to what extent different medications used in intensive care such as antibiotics and also other substances such as painkillers, sedatives, cardiovascular drugs and anticoagulants are similarly retained by the adsorber. In in-vitro studies it could be shown that the investigated adsorber removes a significant amount of an anticoagulant-inhibitor (rivaroxaban) from the blood. This finding is of direct clinical relevance: patients who take this anticoagulant-inhibitor and require emergency surgery cannot be subjected to surgery before the active agent has been completely excreted from the body – a process that can take up to eight hours. The adsorber could notably reduce this waiting time, thereby gaining valuable therapy time. Further investigations into the removal of various other interesting substance classes are scheduled for 2018.

EXSIM – Extracorporeal simulation & models

The EXSIM project area primarily evaluates the therapeutic and toxic effects (hepatotoxicity) of innovative active ingredient components with the aid of in vitro and in vivo models.


Biosensor technology for the prevention or early detection of liver failure

Liver failure is associated with a high mortality rate and can be caused by acute liver diseases or by the deterioration of an existing liver disease. However, medication such as paracetamol may also cause acute liver failure. Liver damage caused by medication is the most common reason for withdrawing drugs that have already been approved for the market. However, there is no reliable test system available at present to detect liver failure at an early stage. This gave rise to the development of a microtiter plate assay based on human liver cells that can be used to detect liver failure at an early stage in a clinical setting and to evaluate the toxicity of drugs and medical devices. By optimizing and standardizing the procedure, reliable statements can be made with regard to exogenous, and also endogenous, toxicity.

Clay minerals in the treatment of CKD and CIBD

The use of clay minerals represents an innovative therapeutic approach in the treatment of chronic inflammatory bowel disease (CIBD). The therapeutic and prophylactic potential of the envisaged clay minerals is currently being characterized in detail with the aid of cell-based models and animal trials. Besides the positive therapeutic and prophylactic effects in the case of CIBD, clay minerals have already been proven to have no toxic potential. The applied clay minerals are assumed to have effects which strengthen the intestinal barrier, such as an antioxidant potential, as well as the ability to bind endotoxins and thus support the treatment of CIBD.

An additional field of application uses clay minerals as phosphate binders in patients suffering from chronic kidney disease (CKD). Patients with renal insufficiency often suffer from much higher phosphate concentrations in the blood serum, which can lead to cardiovascular diseases. To counter this, the phosphate-binding capacity of clay minerals is currently being investigated in a new therapeutic approach with regard to the prevention of cardiovascular diseases. The therapeutic potential is currently being analyzed using an in vitro calcification model for human coronary artery smooth muscle cells (HCASMC) and also in animal trials involving rats with chronic renal failure (5/6 nephrectomy, 5/6 NX).

ECOS – Study center for extracorporeal methods and biosimulation

In order to translate the scientific concepts of the project group into clinical applications in a timely manner, the ECOS study center has now been integrated into the group. On the one hand, the study center will be dedicated to implementing its own scientific concepts and developments in practice; on the other, it shall conduct clinical and preclinical trials in the field of medical extracorporeal therapies and systems on behalf of industry partners and in close cooperation with the University of Rostock's Department of Medicine (UMR) and local hospitals. The research concerns both interventional and non-interventional trials with drugs and medical devices. Our chain of competence here covers all aspects of clinical trials, from planning over to conduct and monitoring through to biometric evaluation and publication. Another key research area lies in analyzing the spread, causes and processes as well as the influencing factors and interactions of diseases in the field of indication, based on clinical and representative population data.

At present, ECOS is involved in a multicenter clinical trial investigating the efficacy and safety of the extracorporeal liver assist device ELAD® in patients with severe alcoholic hepatitis. Two additional observational studies will investigate the effectiveness of using different adsorbers in albumin dialysis and / or for the treatment of patients with severe sepsis.

The Fraunhofer unit in Rostock mainly works in the areas of blood purification and detoxification therapies.

Medical device development

  • In vitro models for extracorporeal methods (organ support outside the patient's body)
  • Process development (e.g. new methods for liver replacement therapy)
  • Creating prototypes
  • Constructing bioreactors
  • Analyzing functional models (e.g. testing dialysis membranes or adsorber cartridges)

Diagnostic and therapeutic cell cultures

  • In-vitro toxicity according to ISO 10933-5 for medical products
  • Analysis of hepatotoxicity (drugs and medical products)
  • Biosensor technology: Early detection of liver failure
  • Producing immune cell concentrates (accumulating granulocytes from whole blood)

Chemical analysis (GCMS, LCMS)

  • Endotoxins
  • Lipophilic protein ligands (especially albumin-bound toxins)

Clinical trials

  • Preclinical and clinical trials with large patient populations
  • Study design, conduct and evaluation
  • Regulatory aspects

Clinical expertise

  • Nephrology
  • Dialysis
  • Intensive medicine
  • Sepsis

  • Albutec GmbH
  • ALLMED Medical GmbH
  • Analytic Jena AG
  • Artcline GmbH
  • BioArtProducts GmbH
  • CytoSorbents Europe GmbH
  • Fibron GmbH
  • FIM Biotech GmbH
  • Furtwangen University, Faculty Medical and Life Sciences (MLS)
  • Gambro Dialysatoren GmbH
  • infomed – Blood purification devices
  • Leib­niz In­sti­tu­te for Plas­ma Sci­ence and Tech­no­lo­gy
  • PRIMACYT Cell Culture Technology GmbH
  • Serumwerk Bernburg AG
  • University Hospital Rostock, Center for Internal Medicine, Clinic II, Department of Gastroenterology
  • University of Greifswald, University Medicine, Institute for Immunology and Transfusion Medicine
  • University of Rostock, Center for Internal Medicine, Clinic II, Department for Nephrology
  • University of Rostock, Faculty of Medicine, Institute for Transfusion Medicine
  • Vital Therapies, Inc.


  • Koertge A, Wasserkort R, Wild T, Mitzner S. Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Critical Accumulation of Rivaroxaban. Blood Purification 45 (2018), 126–128.
  • Koertge A, Wild T, Heskamp B, Folk M, Mitzner S, Wasserkort R. Thrombogenicity and long-term cytokine removal capability of a novel asymmetric triacetate membrane hemofilter. Journal of artificial organs 21 (2018), 4, S. 435-442.
  • Peters F, Westphal C, Kramer A, Westerman R. Is the rise in the prevalence of renal replacement therapy at older ages the price for living longer? Frontiers in Public Health 6 (2018), 138, 7 S.
  • Sauer M, Haubner C, Richter G, Ehler J, Mencke T, Mitzner S, Margraf S, Altrichter J, Doß S, Nöldge-Schomburg G v. Impaired cell viability and functionality of hepatocytes after incubation with septic plasma-results of a second prospective biosensor study. Frontiers in Immunology. 9 (2018), 1448.
  • Sauer M, Richter G, Altrichter J, Wild T, Doß F, Mencke T, Ehler J, Doß S, Koch S, Schubert A, Nöldge-Schomburg G, Mitzner SR. Effects of Bioreactor-Oxygenation During Extracorporeal Granulocytes Treatment in Septic Patients. Therapeutic apheresis and dialysis 22 (2018), 4, S. 389-398.
  • Schäffler H, Breitrück A. Clostridium difficile - from colonization to infection. Frontiers in Microbiology 9 (2018), 646.
  • Frimmel S, Mitzner SR, Koball S. Immunoadsorption as a Long-Term Therapy in Recurrent Focal Segmental Glomerulosclerosis After Renal Transplantation. Therapeutic apheresis and dialysis. 21 (2017), 1, S. 108-109.
  • Doß S, Potschka H, Doß F, Mitzner S, Sauer M. Hepatotoxicity of antimycotics used for invasive fungal infections: In vitro results. BioMed research international 2017 (2017), Art. 9658018, 10 S.
  • Rekers NV, Bajema IM, Mallat MJ, Petersen B, Anholts JD, Swings GM, van Miert PP, Kerkhoff C, Roth J, Popp D, van Groningen MC, Baeten D, Goemaere N, Kraaij MD, Zandbergen M, Heidt S, van Kooten C, de Fijter JW, Claas FH, Eikmans M. Beneficial immune effects of myeloid-related proteins in kidney transplant rejection. American journal of transplantation. 16 (2016), 5, S. 1441-1455.
  • Sauer M, Altrichter J, Haubner C, Pertschy A, Wild T, Doß F, Mencke T, Thomsen M, Ehler J, Henschel J, Doß S, Koch S, Richter G, Nöldge-Schomburg G, Mitzner SR. Bioartificial therapy of sepsis : Changes of norepinephrine-dosage in patients and influence on dynamic and cell based liver tests during extracorporeal treatments. BioMed research international. (2016), Art. 7056492, 11 S.
  • Sombetzki M, Koslowski N, Doss S, Loebermann M, Trauner M, Reisinger EC, Sauer M. Biosensor for hepatocellular injury corresponds to experimental scoring of hepatosplenic schistosomiasis in mice. BioMed research international. (2016), Art. 1567254, 7 S.
  • Sponholz C, Matthes K, Rupp D, Backaus W, Klammt S, Karailieva D, Bauschke A, Settmacher U, Kohl M, Clemens MG, Mitzner S, Bauer M, Kortgen A. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure : A prospective, randomised crossover study. Critical care. 20(2016), Art. 2.
  • Ehler J, Koball S, Sauer M, Mitzner S, Hickstein H, Benecke R, Zettl UK. Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients. Plos One 2015 Aug 5;10(8):e0134583. DOI eCollection 2015
  • Maruschke M, Riebold D, Holtfreter MC, Sombetzki M, Mitzner S, Loebermann M, Reisinger EC, Hakenberg OW. Pneumocystis pneumonia (PCP) and Pneumocystis jirovecii carriage in renal transplantation patients: a single-centre experience. Wien Klin Wochenschr. 2014 Dec;126(23-24):762-6.
  • Frimmel S, Schipper J, Henschel J, Yu TT, Mitzner SR, Koball S. First description of single-pass albumin dialysis combined with cytokine adsorption in fulminant liver failure and hemophagocytic syndrome resulting from generalized herpes simplex virus 1 infection. Liver Transpl. 2014 Dec;20(12):1523-4.
  • Klammt S, Mitzner SR, Reisinger EC, Stange J. No sustained impact of intermittent extracorporeal liver support on thrombocyte time course in a randomized controlled albumin dialysis trial. Ther Apher Dial. 2014 Oct;18(5):502-8.
  • Mencke T, Jacobs RM, Machmueller S, Sauer M, Heidecke C, Kallert A, Pau HW, Noeldge-Schomburg G, Ovari A. Intubating conditions and side effects of propofol, remifentanil and sevoflurane compared with propofol, remifentanil and rocuronium: a randomised, prospective, clinical trial. BMC Anesthesiology 2014; DOI
  • Ehler J, Koball S, Sauer M, Hickstein H, Mitzner S, Benecke R, Zettl UK. Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome. Therapeutic Apheresis and Dialysis. 2014 Oct;18(5):489-96.DOI
  • Frimmel S, Schipper J, Henschel J, Yu TT, Mitzner SR, Koball S. First description of single-pass albumin dialysis combined with cytokine adsorption in fulminant liver failure and hemophagocytic syndrome resulting from generalized herpes simplex virus 1 infection. Liver Transplantation. 2014 Dec;20(12):1523-4. DOI
  • Klammt S, Mitzner SR, Reisinger EC, Stange J. No sustained impact of intermittent extracorporeal liver support on thrombocyte time course in a randomized controlled albumin dialysis trial. Therapeutic Apheresis and Dialysis. 2014 Oct;18(5):502-8. DOI
  • Breitrück A, Sparmann G, Mitzner S, Kerkhoff C. Establishment of a novel extracorporeal bowel model to study luminal approaches to treat inflammatory bowel disease. Dis Model Mech. 2013; 6:1487-1493. DOI
  • Bañares R, Nevens F, Stolze Larsen F, Jalan R, Albillos A, Dollinger M, Saliba F, Sauerbruch T, Klammt S, Ockenga J, Pares A, Wendon J, Brünnler T, Kramer L, Mathurin P, Mata MD, Gasbarrini A, Müllhaupt B, Wilmer A, Laleman W, Eefsen M, Sen S, Zipprich A, Tenorio T, Pavesi M, Schmidt HH, Mitzner S, Williams R, Arroyo V. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology 57 (2013)3: 1153-1162. DOI
  • Mitzner S, Gloger M, Henschel J, Koball S. Improvement of hemodynamic and inflammatory parameters by combined hemoadsorption and hemodiafiltration in septic shock: A case report. Blood purification 35 (2013) 4: 314-315. DOI
  • Sauer M, Altrichter J, Mencke T, Klöhr S, Thomsen M, Kreutzer HJ, Nöldge-Schomburg G, Mitzner S. Role of different replacement fluids during extracorporeal treatment in a pig model of sepsis. Ther Apher Dial. 17 (2013) 1:84-92. DOI
  • Mitzner S. Stellenwert der MARS®-Dialyse beim Acute-on-chronic-Leberversagen: Role of MARS® dialysis in acute-on-chronic liver failure. Z Gastroenterol. 51 (2013) 10: 1193-1194. DOI
  • Averill MM, Kerkhoff C, Bornfeldt KE. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol. 32 (2012), 2, S. 223-9. DOI
  • Kerkhoff C, Voss A, Scholzen TE, Averill MM, Zänker KS, Bornfeldt KE. Novel insights into the role of S100A8/A9 in skin biology. Exp Dermatol. 21 (2012), 11, S. 822 - 6. DOI
  • Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nürnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R; Collaborators of the DGfN STEC-HUS registry. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant. 27 (2012), 10, S. 3807-15. DOI
  • Klammt S, Wojak HJ, Mitzner A, Koball S, Rychly J, Reisinger EC, Mitzner S. Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins. Nephrol Dial Transplant. 27 (2012), 6, S. 2377-83. DOI
  • Klionsky DJ and 1269 others. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 8 (2012), 4, S. 445 - 544. DOI
  • Maletzki C, Bodammer P, Breitrück A, Kerkhoff C. S100 proteins as diagnostic and prognostic markers in colorectal and hepatocellular carcinoma. Hepat Mon. 2012, 12 (10 HCC):e7240. DOI
  • Sauer M, Altrichter J, Mencke T, Klöhr S, Thomsen M, Kreutzer HJ, Nöldge-Schomburg G, Mitzner SR. Plasma separation by centrifugation and subsequent plasma filtration: impact on survival in a pig model of sepsis. Ther Apher Dial. 16 (2012), 3, S. 205-12. DOI
  • Sauer M, Haubner C, Mencke T, Nöldge-Schomburg G, Mitzner S, Altrichter J, Stange J. Impaired cell functions of hepatocytes incubated with plasma of septic patients. Inflamm Res. 61 (2012), 6, S. 609-16. DOI
  • Voss A, Bode G, Kerkhoff C. Double-stranded RNA induces IL-8 and MCP-1 gene expression via TLR3 in HaCaT-keratinocytes. Inflamm Allergy Drug Targets. 11 (2012), 5, S. 397-405.
  • Voss A, Gescher K, Hensel A, Nacken W, Zänker KS, Kerkhoff C. Double-stranded RNA induces S100 gene expression by a cycloheximide-sensitive factor. FEBS Lett. 586 (2012), 2, S. 196-203. DOI
  • Kohl M, Koch S, Keller M, Deigner HP. Biochips: Bright Future in Clinical Dx? J Biochip Tissue chip 2011, S1. DOI



  • Altrichter, J, Mitzner, S, Lübcke A, Selleng K, Doss F, Koch S. Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation. METHOD FOR PRODUCING A LEUKOCYTE PREPARATION, AND LEUKOCYTE PREPARATION. DE 102012209673 A1: 20120608
  • Mitzner S, Kerkhoff C, Bodammer P, Breitrück A, Krüger G. Mineralische Verbindung zur Reduzierung von anorganischen Phosphaten, insbesondere im Rahmen einer Nierenersatztherapie. CLAY MINERAL FOR REDUCING INORGANIC PHOSPHATES, IN PARTICULAR IN RENAL REPLACEMENT THERAPY. DE 102012209411 A1: 20120604
  • Mitzner S, Kerkhoff C, Emmrich F, Breitrueck A, Bodammer P, Krueger G, Dallwig R. Mineralische Verbindung und deren Modifikationen zur Anwendung bei chronisch-entzündlichen Darmerkrankungen. CLAY MINERAL AND ITS MODIFICATIONS FOR USE IN THE TREATMENT OF CHRONIC INFLAMMATORY BOWEL DISEASES. DE 102012207471 A1: 20120504